We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Expression of Nestin, a common marker of neural progenitor cells, is associated with the triple-negative/basal-like phenotype and poor prognosis. Nestin, in a survey of 46 biomarkers, ranked second highest, as well as having 54% sensitivity and 96% specificity for basal-like breast carcinomas (Won, et al, Modern Pathology 2013;26:1438-1450). A 2-marker panel for identification of basal-like breast carcinomas comprised of INPP4B negativity and/or Nestin positivity was observed to have 83% sensitivity and 96% specificity according to published literature (Parry, et al J Clin Pathol 2008;61:1045-1050). Basal-like and/or triple negative breast cancers account for approximately 15% of all breast carcinomas. They are predominately high grade and are associated with early onset, as well as a poor prognosis. The triple negative immunophenotype is known to be an imperfect correlate of the basal-like genotype as determined by molecular studies. Studies have suggested that Nestin might serve as a useful marker of basal-like breast cancers. Using the 10c2 mouse monoclonal antibody to Nestin, we demonstrated 70% sensitivity and 100% specificity, which is higher than the reported literature. Nestin will be run in a panel with other antibodies, including INPP4B, to identify basal-like breast cancers. Subcellular Localization: cytoplasmic
Disease State: Breast Cancer
CPT Code(s): 88342 or 88341 (reference only; CPTs may vary)
Turnaround Time: Within 1-2 business days of receipt
Schedule: Monday - Friday
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR - • 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm